Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia.

Short NJ; Kantarjian H; Jain N; Kadia TM; Senapati J; Haddad FG; Maroun MM; Sasaki K; Xiao L; Huang X; Karrar O; Abramova R; Zhao M; Garris R; Konopleva M; Ravandi F; Jabbour E

doi:10.1182/bloodadvances.2025016565

← 뒤로

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia.

Blood advances 2026 Vol.10(1) p. 25-28

Short NJ, Kantarjian H, Jain N, Kadia TM, Senapati J, Haddad FG, Maroun MM, Sasaki K, Xiao L, Huang X, Karrar O, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Jabbour E

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Short NJ, Kantarjian H, et al. (2026). Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia.. Blood advances, 10(1), 25-28. https://doi.org/10.1182/bloodadvances.2025016565

MLA Short NJ, et al.. "Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia.." Blood advances, vol. 10, no. 1, 2026, pp. 25-28.

PMID 40763277

DOI 10.1182/bloodadvances.2025016565

같은 제1저자의 인용 많은 논문 (1)

Long-term outcomes in -mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor.
Haematologica 2026